JSJonatan Fullerton Støier

Jonatan Fullerton Støier

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jonatan Fullerton Støier has a total of 52 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cover Feature: Discovery of NSD2‐Degraders from Novel and Selective DEL Hits (ChemBioChem 24/2023)

    by Jan LegaardAndersson, Jesper Christensen, Daniela Kleine‐Kohlbrecher, Itys Vacher Comet, Jonatan Fullerton Støier, Yasuko Antoku, Visnja Poljak, Loris Moretti, Johannes Dolberg, Tomas Jacso, et al.

  • Open Access

    Amphetamine-induced reverse transport of dopamine does not require cytosolic Ca2+

    by Jonatan Fullerton Støier, Ainoa Konomi-Pilkati, Mia Apuschkin, Freja Herborg, Ulrik Gether


  • Open Access

    Multimodal detection of dopamine by sniffer cells expressing genetically encoded fluorescent sensors

    by Carmen Klein Herenbrink, Jonatan Fullerton Støier, William Dalseg Reith, Abeer Dagra, Miguel Alejandro Cuadrado Gregorek, Reto B. Cola, Tommaso Patriarchi, Yulong Li, Lin Tian, Ulrik Gether, et al.

    Dopamine supports locomotor control and higher brain functions such as motivation and learning. Consistently, dopaminergic dysfunction is involved in a spectrum of neurological and neuropsychiatric diseases. Detailed data on dopamine dynamics is needed to understand how dopamine signals translate into cellular and behavioral responses, and to uncover pathological disturbances in dopamine-related diseases. Genetically encoded fluorescent dopamine sensors have recently enabled unprecedented monitoring of dopamine dynamics in vivo. However, these sensors’ utility for in vitro and ex vivo assays remains unexplored. Here, we present a blueprint for making dopamine sniffer cells for multimodal dopamine detection. We generated sniffer cell lines with inducible expression of seven different dopamine sensors and perform a head-to-head comparison of sensor properties to guide users in sensor selection. In proof-of-principle experiments, we apply the sniffer cells to record endogenous dopamine release from cultured neurons and striatal slices, and for determining tissue dopamine content. Furthermore, we use the sniffer cells to measure dopamine uptake and release via the dopamine transporter as a radiotracer free, high-throughput alternative to electrochemical- and radiotracer-based assays. Importantly, the sniffer cell framework can readily be applied to the growing list of genetically encoded fluorescent neurotransmitter sensors.


  • Open Access

    α-Synuclein-induced dysregulation of neuronal activity contributes to murine dopamine neuron vulnerability

    by Abeer Dagra, Douglas R. Miller, Min Lin, Adithya Gopinath, Fatemeh Shaerzadeh, Sharonda Harris, Zachary A. Sorrentino, Jonatan Fullerton Støier, Sophia Velasco, Janelle Azar, et al.

    Pathophysiological damages and loss of function of dopamine neurons precede their demise and contribute to the early phases of Parkinson’s disease. The presence of aberrant intracellular pathological inclusions of the protein α-synuclein within ventral midbrain dopaminergic neurons is one of the cardinal features of Parkinson’s disease. We employed molecular biology, electrophysiology, and live-cell imaging to investigate how excessive α-synuclein expression alters multiple characteristics of dopaminergic neuronal dynamics and dopamine transmission in cultured dopamine neurons conditionally expressing GCaMP6f. We found that overexpression of α-synuclein in mouse (male and female) dopaminergic neurons altered neuronal firing properties, calcium dynamics, dopamine release, protein expression, and morphology. Moreover, prolonged exposure to the D2 receptor agonist, quinpirole, rescues many of the alterations induced by α-synuclein overexpression. These studies demonstrate that α-synuclein dysregulation of neuronal activity contributes to the vulnerability of dopaminergic neurons and that modulation of D2 receptor activity can ameliorate the pathophysiology. These findings provide mechanistic insights into the insidious changes in dopaminergic neuronal activity and neuronal loss that characterize Parkinson’s disease progression with significant therapeutic implications.


  • Open Access

    Nanoscopic Dopamine Transporter Distribution and Conformation are Inversely Regulated by Excitatory Drive and D 2-Autoreceptor Activity

    by Matthew D. Lycas, Aske L. Ejdrup, Andreas T. Sørensen, Nicolai O. Haahr, Søren H. Jørgensen, Daryl A. Guthrie, Jonatan F. Støier, Christian Werner, Amy Hauck Newman, Markus Sauer, et al.

    The nanoscopic organization and regulation of individual molecular components in presynaptic varicosities of neurons releasing modulatory volume neurotransmitters like dopamine (DA) remain largely elusive. Here we show by application of several single-molecule sensitive super-resolution microscopy techniques to cultured neurons and mouse striatal slices, that the dopamine transporter (DAT), a key protein in varicosities of dopaminergic neurons, exists in the membrane in dynamic equilibrium between an inward-facing nanodomain-localized and outward-facing unclustered configuration. The balance between these configurations is inversely regulated by excitatory drive and by DA D2-autoreceptor activation in manner dependent on Ca2+-influx via N-type voltage-gated Ca2+-channels. The DAT nanodomains contain tens of transporters molecules and overlap with nanodomains of PIP2 (phosphatidylinositol-4,5-bisphosphate) but show little overlap with D2-autoreceptor, syntaxin-1 and clathrin nanodomains. By demonstrating that nanoscopic reorganizations with putative major impact on transmitter homeostasis can take place in dopaminergic varicosities, the data have important implications for understanding modulatory neurotransmitter physiology.